

# Andr J Scheen

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2271508/andre-j-scheen-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

343  
papers

22,060  
citations

68  
h-index

142  
g-index

391  
ext. papers

25,311  
ext. citations

7.2  
avg, IF

7.91  
L-index

#	Paper	IF	Citations
343	Lower-limb amputations in patients treated with SGLT2 inhibitors versus DPP-4 inhibitors: a meta-analysis of observational studies. <i>Diabetes Epidemiology and Management</i> , <b>2022</b> , 100054		1
342	Lower limb amputations: protection with GLP-1 receptor agonists rather than increased risk with SGLT2 inhibitors?. <i>Diabetes and Metabolism</i> , <b>2022</b> , 48, 101325	5.4	0
341	When therapeutic drugs lead to diabetes.. <i>Diabetologia</i> , <b>2022</b> , 65, 751	10.3	1
340	Understanding the protective effects of SGLT2 inhibitors in type 2 diabetes patients with chronic kidney disease.. <i>Expert Review of Endocrinology and Metabolism</i> , <b>2021</b> , 1-12	4.1	2
339	Association Between the Insertion/Deletion Polymorphism and Risk of Lower-Limb Amputation in Patients With Long-Standing Type 1 Diabetes. <i>Diabetes Care</i> , <b>2021</b> ,	14.6	1
338	Acute renal injury events in diabetic patients treated with SGLT2 inhibitors: A comprehensive review with a special reference to RAAS blockers.. <i>Diabetes and Metabolism</i> , <b>2021</b> , 48, 101315	5.4	0
337	Epidemiology of acute kidney injury adverse events with SGLT2 inhibitors: A meta-analysis of observational cohort studies. <i>Diabetes Epidemiology and Management</i> , <b>2021</b> , 3, 100021		1
336	Could metformin modulate cardiovascular outcomes differently with DPP-4 inhibitors compared with SGLT2 inhibitors?. <i>Diabetes and Metabolism</i> , <b>2021</b> , 47, 101209	5.4	0
335	Careful use to minimize adverse events of oral antidiabetic medications in the elderly. <i>Expert Opinion on Pharmacotherapy</i> , <b>2021</b> , 22, 2149-2165	4	1
334	I/D Polymorphism, Plasma ACE Levels, and Long-term Kidney Outcomes or All-Cause Death in Patients With Type 1 Diabetes. <i>Diabetes Care</i> , <b>2021</b> , 44, 1377-1384	14.6	3
333	Sodium-glucose cotransporter 2 inhibitors: renal outcomes according to baseline albuminuria.. <i>CKJ: Clinical Kidney Journal</i> , <b>2021</b> , 14, 2463-2471	4.5	3
332	L'hopè des insulines des annès 1930 aux annès 1980. <i>Medecine Des Maladies Metaboliques</i> , <b>2021</b> , 15, 3S25-3S31	0.1	0
331	Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2021</b> , 6, 139-147	16.2	16
330	Existe-t-il encore une place pour les sulfamides hypoglycèmants dans le traitement du diabète de type 2 en 2021?. <i>Medecine Des Maladies Metaboliques</i> , <b>2021</b> , 15, 45-52	0.1	
329	DPP-4 inhibition and COVID-19: From initial concerns to recent expectations. <i>Diabetes and Metabolism</i> , <b>2021</b> , 47, 101213	5.4	21
328	Exciting breakthroughs in the management of diabetes mellitus. <i>Diabetes Epidemiology and Management</i> , <b>2021</b> , 1, 100005		1
327	Mèdicaments et prise de poids <b>2021</b> , 91-95		

326	La dysfonction endothéliale : signification clinique et implications thérapeutiques. <i>Medecine Des Maladies Metaboliques</i> , <b>2021</b> , 15, 496-504	0.1	
325	GLP-1 receptor agonists: which added value when increasing the dose?. <i>Lancet Diabetes and Endocrinology,the</i> , <b>2021</b> , 9, 546-548	18.1	1
324	The diuretic effects of SGLT2 inhibitors: A comprehensive review of their specificities and their role in renal protection. <i>Diabetes and Metabolism</i> , <b>2021</b> , 47, 101285	5.4	6
323	Statins and clinical outcomes with COVID-19: Meta-analyses of observational studies. <i>Diabetes and Metabolism</i> , <b>2021</b> , 47, 101220	5.4	16
322	Efficacy / safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes. <i>Diabetes and Metabolism</i> , <b>2021</b> , 47, 101275	5.4	1
321	Sulphonylureas in the management of type 2 diabetes: To be or not to be?. <i>Diabetes Epidemiology and Management</i> , <b>2021</b> , 1, 100002		1
320	Obésité et COVID-19 : le choc fatal entre deux pandémies. <i>Medecine Des Maladies Metaboliques</i> , <b>2020</b> , 14, 437-444	0.1	0
319	Pharmacokinetic/Pharmacodynamic Properties and Clinical Use of SGLT2 Inhibitors in Non-Asian and Asian Patients with Type 2 Diabetes and Chronic Kidney Disease. <i>Clinical Pharmacokinetics</i> , <b>2020</b> , 59, 981-994	6.2	6
318	Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease. <i>Expert Opinion on Drug Safety</i> , <b>2020</b> , 19, 243-256	4.1	10
317	OBEDIS Core Variables Project: European Expert Guidelines on a Minimal Core Set of Variables to Include in Randomized, Controlled Clinical Trials of Obesity Interventions. <i>Obesity Facts</i> , <b>2020</b> , 13, 1-28	5.1	5
316	Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials. <i>Diabetes and Metabolism</i> , <b>2020</b> , 46, 186-196	5.4	13
315	Propos de l'expérience belge avec les inhibiteurs des SGLT2. <i>Medecine Des Maladies Metaboliques</i> , <b>2020</b> , 14, 320-330	0.1	2
314	Prognostic factors in patients with diabetes hospitalized for COVID-19: Findings from the CORONADO study and other recent reports. <i>Diabetes and Metabolism</i> , <b>2020</b> , 46, 265-271	5.4	67
313	Patient-Reported Outcomes with Insulin Glargine 300 U/mL in People with Type 2 Diabetes: The MAGE Multicenter Observational Study. <i>Diabetes Therapy</i> , <b>2020</b> , 11, 1835-1847	3.6	3
312	Glucotoxicité et lipotoxicité dans le diabète de type 2 : comment protéger la cellule β. <i>Medecine Des Maladies Metaboliques</i> , <b>2020</b> , 14, 549-557	0.1	
311	Metformin and COVID-19: From cellular mechanisms to reduced mortality. <i>Diabetes and Metabolism</i> , <b>2020</b> , 46, 423-426	5.4	83
310	Oral semaglutide in Japanese versus non-Japanese patients with type 2 diabetes. <i>Lancet Diabetes and Endocrinology,the</i> , <b>2020</b> , 8, 350-352	18.1	3
309	Traiter le patient diabétique de type 2 à risque : analyse critique des recommandations de l'European Society of Cardiology (ESC). <i>Medecine Des Maladies Metaboliques</i> , <b>2020</b> , 14, 472-481	0.1	1

308	Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. <i>Nature Reviews Endocrinology</i> , <b>2020</b> , 16, 556-577	15.2	67
307	SGLT2 Inhibitors as Add-On Therapy to Metformin for People with Type 2 Diabetes: A Review of Placebo-Controlled Trials in Asian versus Non-Asian Patients. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2020</b> , 13, 2765-2779	3.4	8
306	Series: Implications of the recent CVOTs in type 2 diabetes: Impact on guidelines: The endocrinologist point of view. <i>Diabetes Research and Clinical Practice</i> , <b>2020</b> , 159, 107726	7.4	9
305	SGLT2 inhibitor or GLP-1 receptor agonist in type 2 diabetes?. <i>Lancet Diabetes and Endocrinology</i> , <b>2019</b> , 7, 818-820	18.1	5
304	Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure. <i>Current Cardiology Reports</i> , <b>2019</b> , 21, 70	4.2	41
303	Prise de position de la Société Francophone du Diabète (SFD) : Évaluation du rapport bénéfices-risques des inhibiteurs de SGLT2. <i>Medecine Des Maladies Metaboliques</i> , <b>2019</b> , 13, 195-209	0.1	4
302	An update on the safety of SGLT2 inhibitors. <i>Expert Opinion on Drug Safety</i> , <b>2019</b> , 18, 295-311	4.1	69
301	Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications. <i>Diabetes and Metabolism</i> , <b>2019</b> , 45, 213-223	5.4	68
300	Études cardiovasculaires chez le patient diabétique de type 2 à risque : conclusions et impact des essais publiés en 2017-2018. <i>Medecine Des Maladies Metaboliques</i> , <b>2019</b> , 13, S10-S24	0.1	6
299	Inhibiteurs des SGLT2 et « perte de chance » : une interprétation diamétralement opposée de la Commission de Transparence de la Haute Autorité de Santé (HAS) et de la Société Francophone du Diabète (SFD). <i>Medecine Des Maladies Metaboliques</i> , <b>2019</b> , 13, 309-312	0.1	1
298	Effets des traitements anti-hyperglycémiques sur les complications cardiovasculaires et rénales du patient diabétique de type 2 : leçons des grands essais d'intervention <b>2019</b> , 283-295		
297	Solutions thérapeutiques pour un patient diabétique de type 2 mal contrôlé sous une combinaison metformine plus gliptine. <i>Medecine Des Maladies Metaboliques</i> , <b>2019</b> , 13, 272-279	0.1	1
296	Prise de position de la Société Francophone du Diabète (SFD) sur la prise en charge médicamenteuse de l'hyperglycémie du patient diabétique de type 2 en 2019. <i>Medecine Des Maladies Metaboliques</i> , <b>2019</b> , 13, 711-732	0.1	12
295	Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable. <i>European Heart Journal</i> , <b>2019</b> , 40, 2907-2919	9.5	22
294	Preventing and treating kidney disease in patients with type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , <b>2019</b> , 20, 277-294	4	23
293	Type 2 diabetes mellitus and osteoarthritis. <i>Seminars in Arthritis and Rheumatism</i> , <b>2019</b> , 49, 9-19	5.3	43
292	Why not adding a glucose-lowering agent with proven cardioprotection in high-risk patients with type 2 diabetes at HbA1c target on metformin?. <i>Diabetes Research and Clinical Practice</i> , <b>2019</b> , 147, 169-174	7.4	7
291	Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes. <i>Diabetes and Metabolism</i> , <b>2019</b> , 45, 110-121	5.4	31

290	Place des inhibiteurs des SGLT2 dans le traitement du patient diabétique de type 2. <i>Medecine Des Maladies Metaboliques</i> , <b>2018</b> , 12, 22-30	0.1	8
289	The safety of gliptins : updated data in 2018. <i>Expert Opinion on Drug Safety</i> , <b>2018</b> , 17, 387-405	4.1	70
288	Does lower limb amputation concern all SGLT2 inhibitors?. <i>Nature Reviews Endocrinology</i> , <b>2018</b> , 14, 326-328	3.5	35
287	Type 2 Diabetes and Thiazide Diuretics. <i>Current Diabetes Reports</i> , <b>2018</b> , 18, 6	5.6	15
286	Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype. <i>Diabetes Care</i> , <b>2018</b> , 41, 596-603	14.6	44
285	New hope for glucokinase activators in type 2 diabetes?. <i>Lancet Diabetes and Endocrinology</i> , <b>2018</b> , 6, 591-593	18.1	10
284	Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 620-628	6.7	89
283	The safety of empagliflozin plus metformin for the treatment of type 2 diabetes. <i>Expert Opinion on Drug Safety</i> , <b>2018</b> , 17, 837-848	4.1	3
282	Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors. <i>Circulation Research</i> , <b>2018</b> , 122, 1439-1459	15.7	148
281	Weight loss expectations and determinants in a large community-based sample. <i>Preventive Medicine Reports</i> , <b>2018</b> , 12, 12-19	2.6	2
280	Haemoglobin A1c and 5-year all-cause mortality in French type 2 diabetic patients aged 70 years and older: The GERODIAB observational cohort. <i>Diabetes and Metabolism</i> , <b>2018</b> , 44, 465-472	5.4	15
279	Cardiovascular safety of DPP-4 inhibitors compared with sulphonylureas: Results of randomized controlled trials and observational studies. <i>Diabetes and Metabolism</i> , <b>2018</b> , 44, 386-392	5.4	19
278	Diabetes: Metformin - a cardiovascular moderator of DPP4 inhibitors?. <i>Nature Reviews Endocrinology</i> , <b>2018</b> , 14, 8-9	15.2	7
277	Renal outcomes with dipeptidyl peptidase-4 inhibitors. <i>Diabetes and Metabolism</i> , <b>2018</b> , 44, 101-111	5.4	18
276	Do Positive Cardiovascular Outcomes Trials With New Glucose-Lowering Agents Overestimate Both Efficacy and Safety?. <i>Circulation Research</i> , <b>2018</b> , 123, e3-e4	15.7	
275	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. <i>Lancet, The</i> , <b>2018</b> , 392, 1519-1529	40	771
274	Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease. <i>Diabetes and Metabolism</i> , <b>2018</b> , 44, 457-464	5.4	133
273	Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study. <i>Diabetes Care</i> , <b>2018</b> , 41, 2552-2559	14.6	109

272	Perspectives dans le traitement pharmacologique du diabète de type 2 pour les 10 prochaines années. <i>Medecine Des Maladies Metaboliques</i> , <b>2018</b> , 12, 174-181	0.1	1
271	Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists. <i>Diabetes Research and Clinical Practice</i> , <b>2018</b> , 143, 88-100	7.4	28
270	Relations entre gain barorflexe et autres marqueurs de risque chez le patient diabétique de type 2. <i>Annales De Cardiologie Et D'Angéiologie</i> , <b>2017</b> , 66, 1-6	0.5	0
269	Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME. <i>Diabetes and Metabolism</i> , <b>2017</b> , 43, 99-109	5.4	27
268	Semaglutide: a promising new glucagon-like peptide-1 receptor agonist. <i>Lancet Diabetes and Endocrinology</i> , <b>2017</b> , 5, 236-238	18.1	12
267	Pharmacotherapy of 'treatment resistant' type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , <b>2017</b> , 18, 503-515	4	17
266	3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. <i>Lancet, The</i> , <b>2017</b> , 389, 1399-1409	40	324
265	SGLT2 inhibitor empagliflozin reduces renal outcomes and dampens the progressive reduction in glomerular filtration rate in patients with type 2 diabetes and antecedents of cardiovascular disease. <i>Evidence-Based Medicine</i> , <b>2017</b> , 22, 69-70		
264	Dulaglutide for the treatment of type 2 diabetes. <i>Expert Opinion on Biological Therapy</i> , <b>2017</b> , 17, 485-496	5.4	20
263	GLP-1 receptor agonists and heart failure in diabetes. <i>Diabetes and Metabolism</i> , <b>2017</b> , 43 Suppl 1, S13-S19	5.19	37
262	Impact of glucose-lowering therapies on risk of stroke in type 2 diabetes. <i>Diabetes and Metabolism</i> , <b>2017</b> , 43, 299-313	5.4	16
261	Cardiovascular outcome studies with incretin-based therapies: Comparison between DPP-4 inhibitors and GLP-1 receptor agonists. <i>Diabetes Research and Clinical Practice</i> , <b>2017</b> , 127, 224-237	7.4	11
260	Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2017</b> , 13, 583-592	5.5	7
259	Possible survivorship bias rather than reverse causality in EMPA-REG OUTCOME. <i>Diabetes Research and Clinical Practice</i> , <b>2017</b> , 127, 290	7.4	3
258	Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes. <i>Clinical Pharmacokinetics</i> , <b>2017</b> , 56, 703-718	6.2	28
257	Understanding and overcoming metformin gastrointestinal intolerance. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 473-481	6.7	83
256	Factors associated with reaching or not reaching target HbA <sub>1c</sub> after initiation of basal or premixed insulin in patients with type 2 diabetes. <i>Diabetes and Metabolism</i> , <b>2017</b> , 43, 69-78	5.4	6
255	Prise de position de la Société Francophone du Diabète (SFD) sur la prise en charge médicamenteuse de l'hyperglycémie du patient diabétique de type 2. <i>Medecine Des Maladies Metaboliques</i> , <b>2017</b> , 11, 577-593	0.1	34

254	Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes. <i>Expert Review of Clinical Pharmacology</i> , <b>2017</b> , 10, 1303-1316	3.8	4
253	Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes. <i>Expert Opinion on Investigational Drugs</i> , <b>2017</b> , 26, 1373-1389	5.9	43
252	Canagliflozin: A Review in Type 2 Diabetes. <i>Drugs</i> , <b>2017</b> , 77, 1577-1592	12.1	21
251	Pharmacological management of type 2 diabetes: what's new in 2017?. <i>Expert Review of Clinical Pharmacology</i> , <b>2017</b> , 10, 1383-1394	3.8	16
250	Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , <b>2017</b> , 5, 864-876	18.1	174
249	Discrepancies between the Cockcroft-Gault and Chronic Kidney Disease Epidemiology (CKD-EPI) Equations: Implications for Refining Drug Dosage Adjustment Strategies. <i>Clinical Pharmacokinetics</i> , <b>2017</b> , 56, 193-205	6.2	21
248	Hypoglycemic State, Nondiabetic <b>2017</b> , 270-274		
247	Protection cardio-rhale par les inhibiteurs des SGLT2 (gliflozines) : dâEMPA-REG OUTCOME ^ CANVAS. <i>Revue Medicale Suisse</i> , <b>2017</b> , 13, 1421-1426	2	3
246	SGLT2 Inhibitors: Benefit/Risk Balance. <i>Current Diabetes Reports</i> , <b>2016</b> , 16, 92	5.6	64
245	DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2016</b> , 12, 1407-1417	5.5	57
244	Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics. <i>Diabetes and Metabolism</i> , <b>2016</b> , 42, 224-33	5.4	55
243	Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis. <i>Diabetes and Metabolism</i> , <b>2016</b> , 42, 71-6	5.4	42
242	Dulaglutide (LY-2189265) for the treatment of type 2 diabetes. <i>Expert Review of Clinical Pharmacology</i> , <b>2016</b> , 9, 385-99	3.8	15
241	Investigational insulin secretagogues for type 2 diabetes. <i>Expert Opinion on Investigational Drugs</i> , <b>2016</b> , 25, 405-22	5.9	30
240	Body image discrepancy and subjective norm as mediators and moderators of the relationship between body mass index and quality of life. <i>Patient Preference and Adherence</i> , <b>2016</b> , 10, 2261-2270	2.4	6
239	Cibler la voie mtabolique du cortisol comme action thfapeutique dans le diabte de type 2. <i>Medecine Des Maladies Metaboliques</i> , <b>2016</b> , 10, 725-731	0.1	
238	Effect of Rifampin on the Disposition of Brivaracetam in Human Subjects: Further Insights into Brivaracetam Hydrolysis. <i>Drug Metabolism and Disposition</i> , <b>2016</b> , 44, 792-9	4	30
237	Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2016</b> , 2, 200-5	6.4	21

236	Precision medicine: The future in diabetes care?. <i>Diabetes Research and Clinical Practice</i> , <b>2016</b> , 117, 12-21	7.4	32
235	Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME. <i>Diabetes Research and Clinical Practice</i> , <b>2016</b> , 121, 204-214	7.4	33
234	Clinical inertia in general practice, a matter of debate: a qualitative study with 114 general practitioners in Belgium. <i>BMC Family Practice</i> , <b>2015</b> , 16, 13	2.6	14
233	Obese subjects involvement in a population-based survey: the use of information and communication technologies (ICT) to avoid stigmatization. <i>Quality of Life Research</i> , <b>2015</b> , 24, 1131-5	3.7	3
232	Individualizing treatment of type 2 diabetes by targeting postprandial or fasting hyperglycaemia: Response to a basal vs a premixed insulin regimen by HbA1c quartiles and ethnicity. <i>Diabetes and Metabolism</i> , <b>2015</b> , 41, 216-22	5.4	11
231	Author's reply to De Ponti et al.: "Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus". <i>Clinical Pharmacokinetics</i> , <b>2015</b> , 54, 449-51	6.2	
230	Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2015</b> , 11, 1005-20	5.5	7
229	Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control. <i>Diabetes and Metabolism</i> , <b>2015</b> , 41, 183-94	5.4	97
228	Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. <i>Clinical Pharmacokinetics</i> , <b>2015</b> , 54, 691-708	6.2	105
227	Metformin should not be contraindicated in patients with type 2 diabetes and mild to moderate renal impairment. <i>Evidence-Based Medicine</i> , <b>2015</b> , 20, 115		2
226	SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment. <i>Expert Opinion on Drug Safety</i> , <b>2015</b> , 14, 1879-904	4.1	49
225	Cardiovascular safety of albiglutide and other glucagon-like peptide-1 receptor agonists. <i>Lancet Diabetes and Endocrinology</i> , <b>2015</b> , 3, 667-9	18.1	7
224	Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. <i>Drugs</i> , <b>2015</b> , 75, 33-59	12.1	311
223	Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes. <i>Clinical Pharmacokinetics</i> , <b>2015</b> , 54, 1-21	6.2	73
222	Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease. <i>Expert Opinion on Investigational Drugs</i> , <b>2015</b> , 24, 283-307	5.9	156
221	A Randomized, Double-Blind, Parallel Study to Evaluate the Dose-Response of Three Different Vitamin D Treatment Schemes on the 25-Hydroxyvitamin D Serum Concentration in Patients with Vitamin D Deficiency. <i>Nutrients</i> , <b>2015</b> , 7, 5413-22	6.7	13
220	Weight management in type 2 diabetes: current and emerging approaches to treatment. <i>Diabetes Care</i> , <b>2015</b> , 38, 1161-72	14.6	129
219	Inflammatory markers and cardiometabolic diseases. <i>Acta Clinica Belgica</i> , <b>2015</b> , 70, 193-9	1.8	50



218	Insulinosensibilisateurs (metformine/glitazones) : niveau de preuve et controverse. <i>Medecine Des Maladies Metaboliques</i> , <b>2015</b> , 9, 759-767	0.1	
217	A review of gliptins for 2014. <i>Expert Opinion on Pharmacotherapy</i> , <b>2015</b> , 16, 43-62	4	81
216	Effect of brivaracetam on CYP3A activity, measured by oral midazolam. <i>Journal of Clinical Pharmacology</i> , <b>2015</b> , 55, 543-8	2.9	18
215	Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. <i>Expert Opinion on Drug Safety</i> , <b>2015</b> , 14, 505-24	4.1	80
214	Once-weekly DPP-4 inhibitors: do they meet an unmet need?. <i>Lancet Diabetes and Endocrinology,the</i> , <b>2015</b> , 3, 162-4	18.1	10
213	Obesity. A new paradigm for treating obesity and diabetes mellitus. <i>Nature Reviews Endocrinology</i> , <b>2015</b> , 11, 196-8	15.2	12
212	Towards a genotype-based approach for a patient-centered pharmacologic therapy of type 2 diabetes. <i>Annals of Translational Medicine</i> , <b>2015</b> , 3, S36	3.2	1
211	Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus. <i>Clinical Pharmacokinetics</i> , <b>2014</b> , 53, 295-304	6.2	51
210	Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. <i>Clinical Pharmacokinetics</i> , <b>2014</b> , 53, 213-225	6.2	108
209	Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , <b>2014</b> , 105, 141-50	7.4	1039
208	Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus. <i>Clinical Pharmacokinetics</i> , <b>2014</b> , 53, 773-85	6.2	31
207	Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2014</b> , 10, 647-63	5.5	47
206	Free fatty acids as modulators of the NLRP3 inflammasome in obesity/type 2 diabetes. <i>Biochemical Pharmacology</i> , <b>2014</b> , 92, 131-41	6	110
205	Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2014</b> , 10, 839-57	5.5	35
204	Which incretin-based therapy for type 2 diabetes?. <i>Lancet, The</i> , <b>2014</b> , 384, 1325-7	40	10
203	Personalising metformin therapy: a clinician's perspective. <i>Lancet Diabetes and Endocrinology,the</i> , <b>2014</b> , 2, 442-4	18.1	7
202	Factors associated with clinical inertia: an integrative review. <i>Advances in Medical Education and Practice</i> , <b>2014</b> , 5, 141-7	1.5	59
201	Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence. <i>Diabetes and Metabolism</i> , <b>2014</b> , 40, S4-S11	5.4	71

200	Alogliptin: concern about hepatotoxicity?. <i>Clinical Pharmacokinetics</i> , <b>2014</b> , 53, 1057-9	6.2	11
199	Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , <b>2014</b> , 2, 911-22	18.1	123
198	Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: a critical reappraisal. <i>Diabetes and Metabolism</i> , <b>2014</b> , 40, 176-85	5.4	51
197	SGLT2 versus DPP4 inhibitors for type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , <b>2013</b> , 1, 168-70	18.1	18
196	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). <i>European Heart Journal</i> , <b>2013</b> , 34, 3035-87	9.5	1444
195	Obesity phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue. <i>Diabetologia</i> , <b>2013</b> , 56, 2487-97	10.3	152
194	Efficacy and safety of Jentaduet <sup>®</sup> (linagliptin plus metformin). <i>Expert Opinion on Drug Safety</i> , <b>2013</b> , 12, 275-89	4.1	6
193	Cardiovascular risk factors and complications associated with albuminuria and impaired renal function in insulin-treated diabetes. <i>Journal of Diabetes and Its Complications</i> , <b>2013</b> , 27, 370-5	3.2	7
192	GLP-1 receptor agonists or DPP-4 inhibitors: how to guide the clinician?. <i>Annales D'Endocrinologie</i> , <b>2013</b> , 74, 515-22	1.7	17
191	Cardiovascular effects of gliptins. <i>Nature Reviews Cardiology</i> , <b>2013</b> , 10, 73-84	14.8	138
190	Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. <i>Diabetes and Metabolism</i> , <b>2013</b> , 39, 179-90	5.4	115
189	Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis. <i>Expert Opinion on Drug Safety</i> , <b>2013</b> , 12, 545-57	4.1	35
188	Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2013</b> , 9, 529-50	5.5	64
187	Issues in performing a network meta-analysis. <i>Statistical Methods in Medical Research</i> , <b>2013</b> , 22, 169-89	2.3	48
186	Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes. <i>Postgraduate Medicine</i> , <b>2013</b> , 125, 7-20	3.7	62
185	Unsaturated fatty acids prevent activation of NLRP3 inflammasome in human monocytes/macrophages. <i>Journal of Lipid Research</i> , <b>2013</b> , 54, 2998-3008	6.3	101
184	Critical assessment of diabetic xerosis. <i>Expert Opinion on Medical Diagnostics</i> , <b>2013</b> , 7, 201-7		10
183	Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2013</b> , 9, 363-77	5.5	9

182	The skin landscape in diabetes mellitus. Focus on dermocosmetic management. <i>Clinical, Cosmetic and Investigational Dermatology</i> , <b>2013</b> , 6, 127-35	2.9	14
181	Squatting test: a dynamic postural manoeuvre to study baroreflex sensitivity. <i>Clinical Autonomic Research</i> , <b>2012</b> , 22, 35-41	4.3	10
180	Gliptin versus a sulphonylurea as add-on to metformin. <i>Lancet, The</i> , <b>2012</b> , 380, 450-2	4.0	23
179	Metformin + saxagliptin for type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , <b>2012</b> , 13, 139-46	4	16
178	Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: results from a 3-month prospective open-label study. <i>European Neuropsychopharmacology</i> , <b>2012</b> , 22, 17-26	1.2	33
177	Outcomes and lessons from the PROactive study. <i>Diabetes Research and Clinical Practice</i> , <b>2012</b> , 98, 175-86	4	30
176	Médicaments de lâõbbsit'et risque cardiovasculaire: Anti-obesity drugs and cardiovascular risk. <i>Medecine Des Maladies Metaboliques</i> , <b>2012</b> , 6, 31-37	0.1	
175	Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2012</b> , 8, 745-58	5.5	7
174	Saxagliptin plus metformin combination therapy. <i>Expert Review of Endocrinology and Metabolism</i> , <b>2012</b> , 7, 151-164	4.1	2
173	Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2012</b> , 8, 383-94	5.5	9
172	Haemodynamic changes during a squat test, pulsatile stress and indices of cardiovascular autonomic neuropathy in patients with long-duration type 1 diabetes. <i>Diabetes and Metabolism</i> , <b>2012</b> , 38, 54-62	5.4	4
171	DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. <i>Diabetes and Metabolism</i> , <b>2012</b> , 38, 89-101	5.4	133
170	Dipeptidylpeptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) receptor agonists: yes. <i>European Journal of Internal Medicine</i> , <b>2012</b> , 23, 126-31	3.9	19
169	Controversy about the relative efficacy of dipeptidyl peptidase IV inhibitors. <i>Diabetologia</i> , <b>2012</b> , 55, 2848-2849	3.9	19
168	A review of gliptins in 2011. <i>Expert Opinion on Pharmacotherapy</i> , <b>2012</b> , 13, 81-99	4	91
167	Le tractus digestif comme organe endocrine : une nouvelle vision de la chirurgie bariatrique: The digestive tract as an endocrine organ: Bariatric surgery revisited. <i>Medecine Des Maladies Metaboliques</i> , <b>2011</b> , 5, 155-161	0.1	1
166	Squatting, a posture test for studying cardiovascular autonomic neuropathy in diabetes. <i>Diabetes and Metabolism</i> , <b>2011</b> , 37, 489-96	5.4	11
165	Squatting test: A posture to study and counteract cardiovascular abnormalities associated with autonomic dysfunction. <i>Autonomic Neuroscience: Basic and Clinical</i> , <b>2011</b> , 162, 3-9	2.4	12

164	Facing up to the imperceptible perspiration. Modulatory influences by diabetic neuropathy, physical exercise and antiperspirant. <i>Skin Research and Technology</i> , <b>2011</b> , 17, 487-93	1.9	14
163	Hypocortisolism induces chronic respiratory failure. <i>Respiratory Medicine CME</i> , <b>2011</b> , 4, 107-108		1
162	Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation). <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2011</b> , 7, 1561-76	5.5	27
161	Sibutramine on cardiovascular outcome. <i>Diabetes Care</i> , <b>2011</b> , 34 Suppl 2, S114-9	14.6	34
160	Cytochrome P450-mediated cardiovascular drug interactions. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2011</b> , 7, 1065-82	5.5	21
159	Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. <i>Diabetes, Obesity and Metabolism</i> , <b>2010</b> , 12, 648-58.7	5.7	212
158	Pulsatile stress in middle-aged patients with type 1 or type 2 diabetes compared with nondiabetic control subjects. <i>Diabetes Care</i> , <b>2010</b> , 33, 2424-9	14.6	4
157	Effect of valsartan on the incidence of diabetes and cardiovascular events. <i>New England Journal of Medicine</i> , <b>2010</b> , 362, 1477-90	59.2	493
156	Effect of nateglinide on the incidence of diabetes and cardiovascular events. <i>New England Journal of Medicine</i> , <b>2010</b> , 362, 1463-76	59.2	358
155	Aptitude physique versus adiposité: impacts métaboliques respectifs chez le sujet avec une diminution de la tolérance au glucose ou un diabète de type 2. <i>Medecine Des Maladies Metaboliques</i> , <b>2010</b> , 4, 673-680	0.1	2
154	L'hyperglycémie provoquée par voie orale (HGPO) revisitée. <i>Medecine Des Maladies Metaboliques</i> , <b>2010</b> , 4, 684-690	0.1	1
153	L'hyperglycémie provoquée par voie orale (HGPO) revisitée: The Oral Glucose Tolerance Test (OGTT) revisited. <i>Medecine Des Maladies Metaboliques</i> , <b>2010</b> , 4, 569-574	0.1	2
152	Aptitude physique versus adiposité: aspects physiopathologiques et impacts cardio-métaboliques chez le sujet adulte non diabétique. <i>Medecine Des Maladies Metaboliques</i> , <b>2010</b> , 4, 291-298	0.1	2
151	Aptitude physique versus adiposité: impacts cardio-métaboliques respectifs chez l'enfant/adolescent et chez la personne âgée. <i>Medecine Des Maladies Metaboliques</i> , <b>2010</b> , 4, 395-401	0.1	2
150	Maladie cardiovasculaire et diabète chez les personnes atteintes d'une maladie mentale sévère: 1re partie. Épidémiologie et influence des médicaments psychotropes*. <i>Medecine Des Maladies Metaboliques</i> , <b>2010</b> , 4, 93-102	0.1	5
149	Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2010</b> , 6, 1265-76	5.5	24
148	Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. <i>Clinical Pharmacokinetics</i> , <b>2010</b> , 49, 573-88	6.2	119
147	Controversy about the cardiovascular safety of sibutramine. <i>Drug Safety</i> , <b>2010</b> , 33, 615-8	5.1	3

146	Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19). <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2010</b> , 95, 2163-71	5.6	50
145	Addition of incretin therapy to metformin in type 2 diabetes. <i>Lancet, The</i> , <b>2010</b> , 375, 1410-2	4.0	34
144	Continuous glucose monitoring reduces both hypoglycaemia and HbA1c in hypoglycaemia-prone type 1 diabetic patients treated with a portable pump. <i>Diabetes and Metabolism</i> , <b>2010</b> , 36, 409-13	5.4	18
143	Central nervous system: a conductor orchestrating metabolic regulations harmed by both hyperglycaemia and hypoglycaemia. <i>Diabetes and Metabolism</i> , <b>2010</b> , 36 Suppl 3, S31-8	5.4	35
142	Cardiovascular risk-benefit profile of sibutramine. <i>American Journal of Cardiovascular Drugs</i> , <b>2010</b> , 10, 321-34	4	60
141	Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. <i>Diabetes/Metabolism Research and Reviews</i> , <b>2010</b> , 26, 540-9	7.5	143
140	Pulse pressure and cardiovascular autonomic neuropathy according to duration of type 1 diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , <b>2009</b> , 25, 442-51	7.5	22
139	Sujets « métaboliquement sains », bien qu'obèses. Première partie: diagnostic, physiopathologie et prévalence. <i>Obesité</i> , <b>2009</b> , 4, 56-65	0.1	3
138	Sujets « métaboliquement sains », bien qu'obèses. Deuxième partie : pronostic et prise en charge. <i>Obesité</i> , <b>2009</b> , 4, 134-141	0.1	1
137	Rôle de l'enzyme 11 $\beta$ -hydroxystéroïde-déshydrogénase de type 1 dans le risque métabolique associé à l'obésité. <i>Obesité</i> , <b>2009</b> , 4, 181-188	0.1	
136	Rosiglitazone: to be or not to be?. <i>Diabetologia</i> , <b>2009</b> , 52, 1448-50	10.3	1
135	Long-term glycaemic control with metformin-sulphonylurea-pioglitazone triple therapy in PROactive (PROactive 17). <i>Diabetic Medicine</i> , <b>2009</b> , 26, 1033-9	3.5	33
134	Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , <b>2009</b> , 23, 103-16	6.5	39
133	La 11 $\beta$ -hydroxystéroïde déshydrogénase de type 1 à l'épreuve. <i>Medicine Des Maladies Métaboliques</i> , <b>2009</b> , 3, 507-513	0.1	2
132	La 11 $\beta$ -hydroxystéroïde déshydrogénase de type 1 à l'épreuve. Deuxième partie Inhibition sélective pour traiter les anomalies métaboliques associées à l'obésité. <i>Medicine Des Maladies Métaboliques</i> , <b>2009</b> , 3, 595-600	0.1	2
131	Bariatric surgery in patients with type 2 diabetes: benefits, risks, indications and perspectives. <i>Diabetes and Metabolism</i> , <b>2009</b> , 35, 537-43	5.4	19
130	Voglibose for prevention of type 2 diabetes mellitus. <i>Lancet, The</i> , <b>2009</b> , 373, 1579-80	4.0	9
129	The endocannabinoid system: a promising target for the management of type 2 diabetes. <i>Current Protein and Peptide Science</i> , <b>2009</b> , 10, 56-74	2.8	20

128	Estimation of GFR by different creatinine- and cystatin-C-based equations in anorexia nervosa. <i>Clinical Nephrology</i> , <b>2009</b> , 71, 482-91	2.1	17
127	Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. <i>Bipolar Disorders</i> , <b>2008</b> , 10, 342-8	3.8	144
126	Abdominal adiposity: Early intervention and therapeutic options. <i>Clinical Cornerstone</i> , <b>2008</b> , 9, S20-S27		4
125	Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. <i>Schizophrenia Research</i> , <b>2008</b> , 101, 295-303	3.6	188
124	A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder. <i>Schizophrenia Research</i> , <b>2008</b> , 106, 308-14	3.6	38
123	Exenatide once weekly in type 2 diabetes. <i>Lancet, The</i> , <b>2008</b> , 372, 1197-8	4.0	20
122	Traitements neuroleptiques et troubles métaboliques. <i>Medecine Des Maladies Metaboliques</i> , <b>2008</b> , 2, 593-599	0.1	4
121	Squatting amplifies pulse pressure increase with disease duration in patients with type 1 diabetes. <i>Diabetes Care</i> , <b>2008</b> , 31, 322-4	14.6	9
120	Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. <i>European Heart Journal</i> , <b>2008</b> , 29, 1761-71	9.5	115
119	Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. <i>Diabetes Care</i> , <b>2008</b> , 31 Suppl 2, S229-40	14.6	159
118	New therapeutic approaches in type 2 diabetes. <i>Acta Clinica Belgica</i> , <b>2008</b> , 63, 402-7	1.8	20
117	Medications in the kidney. <i>Acta Clinica Belgica</i> , <b>2008</b> , 63, 76-80	1.8	12
116	Do thiazolidinediones increase the risk of congestive heart failure and cardiovascular death?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , <b>2008</b> , 4, 260-1		3
115	Inhibitors of cannabinoid receptors and glucose metabolism. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , <b>2008</b> , 11, 505-11	3.8	13
114	Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results. <i>Journal of Hypertension</i> , <b>2008</b> , 26, 357-67	1.9	58
113	Belgian expert opinion: how to reduce the residual risk in atherogenic dyslipidaemic patients: place of fibrates. <i>Acta Cardiologica</i> , <b>2008</b> , 63, 235-48	0.9	6
112	Sujets « métaboliquement obèses » de poids normal. Première partie: diagnostic, physiopathologie et prévalence. <i>Obesite</i> , <b>2008</b> , 3, 184-193	0.1	2
111	Sujets « métaboliquement obèses » de poids normal. Seconde partie: pronostic et prise en charge. <i>Obesite</i> , <b>2008</b> , 3, 280-285	0.1	2

110	Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. <i>Journal of Clinical Psychiatry</i> , <b>2008</b> , 69, 472-9	4.6	70
109	Psychiatric diagnosis as an independent risk factor for metabolic disturbances: results from a comprehensive, naturalistic screening program. <i>Journal of Clinical Psychiatry</i> , <b>2008</b> , 69, 1319-27	4.6	57
108	The safety of obesity drugs. <i>Expert Opinion on Drug Safety</i> , <b>2007</b> , 6, 475-6; author reply 477-8	4.1	
107	Pharmacokinetic interactions with thiazolidinediones. <i>Clinical Pharmacokinetics</i> , <b>2007</b> , 46, 1-12	6.2	41
106	Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. <i>Clinical Pharmacokinetics</i> , <b>2007</b> , 46, 93-108	6.2	56
105	Cannabinoid-1 receptor antagonists in type-2 diabetes. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , <b>2007</b> , 21, 535-53	6.5	19
104	Rimonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes. <i>European Heart Journal</i> , <b>2007</b> , 28, 1401-2; author reply 1402	9.5	4
103	A case series: evaluation of the metabolic safety of aripiprazole. <i>Schizophrenia Bulletin</i> , <b>2007</b> , 33, 823-30	1.3	52
102	Efficacy of indapamide SR compared with enalapril in elderly hypertensive patients with type 2 diabetes. <i>American Journal of Hypertension</i> , <b>2007</b> , 20, 90-7	2.3	17
101	Antidiabetic agents in subjects with mild dysglycaemia: prevention or early treatment of type 2 diabetes?. <i>Diabetes and Metabolism</i> , <b>2007</b> , 33, 3-12	5.4	39
100	Abnormal glucose metabolism in patients treated with antipsychotics. <i>Diabetes and Metabolism</i> , <b>2007</b> , 33, 169-75	5.4	119
99	Rimonabant in obese patients with type 2 diabetes – Authors' reply. <i>Lancet, The</i> , <b>2007</b> , 369, 554-555	4.0	0
98	Lipodystrophy reactions to insulin: effects of continuous insulin infusion and new insulin analogs. <i>American Journal of Clinical Dermatology</i> , <b>2007</b> , 8, 21-8	7.1	57
97	Nutritional Counseling for Overweight Patients and Patients with Metabolic Syndrome <b>2007</b> , 201-211		1
96	Pharmacological treatment of severe dyslipidaemia in patients with schizophrenia. <i>International Clinical Psychopharmacology</i> , <b>2007</b> , 22, 43-9	2.2	31
95	Aspirin and clopidogrel resistance in patients with diabetes mellitus. <i>European Heart Journal</i> , <b>2006</b> , 27, 2900; author reply 2900-1	9.5	12
94	Reversibility of antipsychotic treatment-related diabetes in patients with schizophrenia: a case series of switching to aripiprazole. <i>Diabetes Care</i> , <b>2006</b> , 29, 2329-30	14.6	20
93	Metformin extended release. <i>American Journal of Drug Delivery</i> , <b>2006</b> , 4, 187-188		

92	Does the metabolic syndrome help to select patients requiring high statin dose?. <i>Lancet, The</i> , <b>2006</b> , 368, 893-4	4.0	5
91	Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. <i>Lancet, The</i> , <b>2006</b> , 368, 1660-72	4.0	624
90	Oral glucose tolerance tests in treated patients with schizophrenia. Data to support an adaptation of the proposed guidelines for monitoring of patients on second generation antipsychotics?. <i>European Psychiatry</i> , <b>2006</b> , 21, 224-6	6	23
89	Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. <i>Schizophrenia Research</i> , <b>2006</b> , 83, 87-93	3.6	229
88	Insulin detemir in the treatment of type 1 and type 2 diabetes. <i>Vascular Health and Risk Management</i> , <b>2006</b> , 2, 277-83	4.4	12
87	Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: evaluation of incidence and screening methods. <i>Journal of Clinical Psychiatry</i> , <b>2006</b> , 67, 1493-500	4.6	59
86	Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder. <i>Journal of Clinical Psychiatry</i> , <b>2006</b> , 67, 1889-96	4.6	50
85	Diabetes, Obesity, and Metabolic Syndrome. <i>Nutrition and Disease Prevention</i> , <b>2006</b> , 1-30		
84	Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. <i>Lancet, The</i> , <b>2005</b> , 365, 1389-97	4.0	1252
83	Effect of rimonabant on weight reduction and cardiovascular risk. <i>Lancet, The</i> , <b>2005</b> , 366, 369-370	4.0	12
82	Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAZone Clinical Trial In macroVascular Events): a randomised controlled trial. <i>Lancet, The</i> , <b>2005</b> , 366, 1279-89	4.0	3186
81	Diabetes mellitus in the elderly: insulin resistance and/or impaired insulin secretion?. <i>Diabetes and Metabolism</i> , <b>2005</b> , 31 Spec No 2, 5S27-5S34	5.4	93
80	Drug interactions of clinical importance with antihyperglycaemic agents: an update. <i>Drug Safety</i> , <b>2005</b> , 28, 601-31	5.1	99
79	Drug-eluting stents: meta-analysis in diabetic patients. <i>European Heart Journal</i> , <b>2004</b> , 25, 2167-8; author reply 2168-9	9.5	56
78	Diabetes is still a risk factor for restenosis after drug-eluting stent in coronary arteries. <i>Diabetes Care</i> , <b>2004</b> , 27, 1840-1	14.6	35
77	Continuous subcutaneous insulin infusion with short-acting insulin analogues or human regular insulin: efficacy, safety, quality of life, and cost-effectiveness. <i>Diabetes/Metabolism Research and Reviews</i> , <b>2004</b> , 20, 178-88	7.5	56
76	Acanthosis nigricans associated with insulin resistance : pathophysiology and management. <i>American Journal of Clinical Dermatology</i> , <b>2004</b> , 5, 199-203	7.1	96
75	Pathophysiology of insulin secretion. <i>Annales D'Endocrinologie</i> , <b>2004</b> , 65, 29-36	1.7	22



74	Combined thiazolidinedione-insulin therapy: should we be concerned about safety?. <i>Drug Safety</i> , <b>2004</b> , 27, 841-56	5.1	48
73	Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system. <i>Drugs</i> , <b>2004</b> , 64, 2537-65	12.1	201
72	Tolerability profile of metformin/glibenclamide combination tablets (Glucovance): a new treatment for the management of type 2 diabetes mellitus. <i>Drug Safety</i> , <b>2004</b> , 27, 1205-16	5.1	11
71	Le syndrome métabolique : comparaison des paramètres biologiques dans différentes définitions. <i>Immuno-Analyse Et Biologie Spécialisee</i> , <b>2004</b> , 19, 188-194		1
70	Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. <i>Diabetes and Metabolism</i> , <b>2004</b> , 30, 487-96	5.4	212
69	Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. <i>Diabetes and Metabolism</i> , <b>2004</b> , 30, 498-505	5.4	132
68	VALUE: analysis of results. <i>Lancet, The</i> , <b>2004</b> , 364, 932-3; author reply 935	4.0	14
67	Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. <i>Journal of Hypertension</i> , <b>2004</b> , 22, 1613-22	1.9	98
66	Integrated Approach to Treatment and Prevention <b>2004</b> , 449-463		2
65	Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. <i>Hypertension</i> , <b>2003</b> , 41, 1063-71	8.5	131
64	Treatment of type 2 diabetes. <i>Acta Clinica Belgica</i> , <b>2003</b> , 58, 318-24	1.8	13
63	Evaluation of the immune response to pneumococcal capsular polysaccharides. <i>Acta Clinica Belgica</i> , <b>2003</b> , 58, 106-10	1.8	8
62	Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?. <i>Drugs</i> , <b>2003</b> , 63, 933-51	12.1	157
61	Current management strategies for coexisting diabetes mellitus and obesity. <i>Drugs</i> , <b>2003</b> , 63, 1165-84	12.1	65
60	L'hyperglycémie provoquée par voie orale : de la controverse à un plaidoyer pour sa place en biologie clinique. <i>Immuno-Analyse Et Biologie Spécialisee</i> , <b>2003</b> , 18, 126-132		3
59	L'hyperglycémie provoquée par voie orale. Étude de la sécrétion, de la clairance et de l'action de l'insuline, et du contre-régulation par les hormones de la contre-régulation. <i>Immuno-Analyse Et Biologie Spécialisee</i> , <b>2003</b> , 18, 185-190		2
58	Preventing, delaying, or masking type 2 diabetes with metformin in the diabetes prevention program?. <i>Diabetes Care</i> , <b>2003</b> , 26, 2701; author reply 2701-3	14.6	7
57	Pathophysiology of type 2 diabetes. <i>Acta Clinica Belgica</i> , <b>2003</b> , 58, 335-41	1.8	131

56	Hepatic insulin resistance in obese non-diabetic subjects and in type 2 diabetic patients. <i>Obesity</i> , <b>2002</b> , 10, 129-34		26
55	Potential pharmacokinetics interference between alpha-glucosidase inhibitors and other oral antidiabetic agents. <i>Diabetes Care</i> , <b>2002</b> , 25, 247-8	14.6	7
54	Relation between disease phenotype and HLA-DQ genotype in diabetic patients diagnosed in early adulthood. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2002</b> , 87, 2597-605	5.6	19
53	Obesity and liver disease. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , <b>2002</b> , 16, 703-16	6.5	87
52	Acarbose for type 2 diabetes prevention. <i>Lancet, The</i> , <b>2002</b> , 360, 1516; author reply 1517	40	7
51	Are all glitazones the same?. <i>Diabetes/Metabolism Research and Reviews</i> , <b>2002</b> , 18 Suppl 2, S1-4	7.5	5
50	New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat. <i>Diabetes and Metabolism</i> , <b>2002</b> , 28, 437-45	5.4	32
49	Hepatotoxicity with thiazolidinediones: is it a class effect?. <i>Drug Safety</i> , <b>2001</b> , 24, 873-88	5.1	100
48	Thiazolidinediones and liver toxicity. <i>Diabetes and Metabolism</i> , <b>2001</b> , 27, 305-13	5.4	99
47	From obesity to diabetes: why, when and who?. <i>Acta Clinica Belgica</i> , <b>2000</b> , 55, 9-15	1.8	35
46	Antiobesity pharmacotherapy in the management of type 2 diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , <b>2000</b> , 16, 114-24	7.5	20
45	Assessment of postprandial hepatic glycogen synthesis from uridine diphosphoglucose kinetics in obese and lean non-diabetic subjects. <i>International Journal of Obesity</i> , <b>2000</b> , 24, 1297-302	5.5	4
44	No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2000</b> , 85, 1316-9	5.6	149
43	Exploration et suivi biologique d'un patient obèse. <i>Immuno-Analyse Et Biologie Specialisee</i> , <b>2000</b> , 15, 250-254		2
42	Treatment of diabetes in patients with severe obesity. <i>Biomedicine and Pharmacotherapy</i> , <b>2000</b> , 54, 74-97.5		18
41	Parallel reversibility of biological markers of the metabolic syndrome and liver steatosis after gastroplasty-induced weight loss in severe obesity. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1999</b> , 84, 4293	5.6	17
40	Pharmacological treatment of obesity: present status. <i>International Journal of Obesity</i> , <b>1999</b> , 23 Suppl 1, 47-53	5.5	39
39	CAPPP trial. <i>Lancet, The</i> , <b>1999</b> , 353, 1793-1794	40	5

38	Non-alcoholic steatohepatitis. <i>Lancet, The</i> , <b>1999</b> , 354, 1298-9	40	6
37	Severe/extreme obesity: a medical disease requiring a surgical treatment?. <i>Acta Clinica Belgica</i> , <b>1999</b> , 54, 154-61	1.8	5
36	Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. <i>International Journal of Obesity</i> , <b>1998</b> , 22, 222-6	5.5	348
35	The postprandial state and risk of cardiovascular disease <b>1998</b> , 15, S63-S68		20
34	Oral antidiabetic agents. A guide to selection. <i>Drugs</i> , <b>1998</b> , 55, 225-36	12.1	103
33	The roles of time of day and sleep quality in modulating glucose regulation: clinical implications. <i>Hormone Research in Paediatrics</i> , <b>1998</b> , 49, 191-201	3.3	42
32	Influence of the A-->G (-3826) uncoupling protein-1 gene (UCP1) variant on the dynamics of body weight before and after gastroplasty in morbidly obese subjects. <i>International Journal of Obesity</i> , <b>1998</b> , 22, 1244-5	5.5	5
31	The postprandial state and risk of cardiovascular disease. <i>Diabetic Medicine</i> , <b>1998</b> , 15, S63-S68	3.5	3
30	The postprandial state and risk of cardiovascular disease. <i>Diabetic Medicine</i> , <b>1998</b> , 15 Suppl 4, S63-8	3.5	88
29	Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s. Achievements and future developments. <i>Drugs</i> , <b>1997</b> , 54, 355-68	12.1	97
28	Non-insulin-dependent diabetes mellitus in the elderly. <i>Baillieres Clinical Endocrinology and Metabolism</i> , <b>1997</b> , 11, 389-406		11
27	Clinical pharmacokinetics of metformin. <i>Clinical Pharmacokinetics</i> , <b>1996</b> , 30, 359-71	6.2	401
26	Usefulness of fluoxetine in obese non-insulin-dependent diabetics: a multicenter study. <i>Obesity</i> , <b>1996</b> , 4, 391-6		40
25	Insulin resistance syndrome and atherosclerotic cardiovascular disease. <i>Acta Clinica Belgica</i> , <b>1996</b> , 51, 65-9	1.8	8
24	Treatment with insulin infusion pumps and ketoacidotic episodes: from physiology to troubleshooting. <i>Diabetes/metabolism Reviews</i> , <b>1995</b> , 11, 161-77		6
23	Effects of metformin in obese patients with impaired glucose tolerance. <i>Diabetes/metabolism Reviews</i> , <b>1995</b> , 11 Suppl 1, S69-80		10
22	Métabolisme glucidique pendant l'exercice musculaire prolongé chez l'homme: effet de l'âge. <i>Science and Sports</i> , <b>1995</b> , 10, 123-130	0.8	
21	Short administration of metformin improves insulin sensitivity in android obese subjects with impaired glucose tolerance. <i>Diabetic Medicine</i> , <b>1995</b> , 12, 985-9	3.5	35

20	Antihyperglycaemic agents. Drug interactions of clinical importance. <i>Drug Safety</i> , <b>1995</b> , 12, 32-45	5.1	37
19	How to measure insulin clearance. <i>Diabetes/metabolism Reviews</i> , <b>1994</b> , 10, 119-50		46
18	How to measure insulin action in vivo. <i>Diabetes/metabolism Reviews</i> , <b>1994</b> , 10, 151-88		68
17	Therapy for obesity--today and tomorrow. <i>Baillieres Clinical Endocrinology and Metabolism</i> , <b>1994</b> , 8, 705-27		7
16	Combination of oral antidiabetic drugs and insulin in the treatment of non-insulin-dependent diabetes. <i>Acta Clinica Belgica</i> , <b>1993</b> , 48, 259-68	1.8	13
15	Effects of a 1-year treatment with a low-dose combined oral contraceptive containing ethinyl estradiol and cyproterone acetate on glucose and insulin metabolism. <i>Fertility and Sterility</i> , <b>1993</b> , 59, 797-802	4.8	18
14	Devices for the treatment of diabetes: today. <i>Artificial Organs</i> , <b>1992</b> , 16, 163-6	2.6	2
13	Management of non-insulin-dependent diabetes mellitus. <i>Drugs</i> , <b>1992</b> , 44 Suppl 3, 29-38	12.1	16
12	Improvement of insulin-induced glucose disposal in obese patients with NIDDM after 1-wk treatment with d-fenfluramine. <i>Diabetes Care</i> , <b>1991</b> , 14, 325-32	14.6	69
11	Pulsatile insulin delivery has greater metabolic effects than continuous hormone administration in man: importance of pulse frequency. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1991</b> , 72, 607-15	5.6	91
10	Effects of ethinyl estradiol combined with desogestrel and cyproterone acetate on glucose tolerance and insulin response to an oral glucose load: a one-year randomized, prospective, comparative trial. <i>American Journal of Obstetrics and Gynecology</i> , <b>1990</b> , 163, 378-81	6.4	14
9	Sandostatin, a new analogue of somatostatin, reduces the metabolic changes induced by the nocturnal interruption of continuous subcutaneous insulin infusion in type 1 (insulin-dependent) diabetic patients. <i>Diabetologia</i> , <b>1989</b> , 32, 801-9	10.3	8
8	Impaired insulin-induced erythrocyte magnesium accumulation is correlated to impaired insulin-mediated glucose disposal in type 2 (non-insulin-dependent) diabetic patients. <i>Diabetologia</i> , <b>1988</b> , 31, 910-5	10.3	43
7	The addition of glipizide to insulin therapy in type-II diabetic patients with secondary failure to sulfonylureas is useful only in the presence of a significant residual insulin secretion. <i>European Journal of Endocrinology</i> , <b>1987</b> , 116, 364-72	6.5	21
6	Primary role of glucagon release in the effect of beta-endorphin on glucose homeostasis in normal man. <i>European Journal of Endocrinology</i> , <b>1987</b> , 115, 161-9	6.5	24
5	Insulin oscillations per se do not affect glucose turnover parameters in normal man. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1986</b> , 63, 520-5	5.6	17
4	Blood collection while using a continuous glucose analyzer without insertion of an additional venous catheter. <i>Diabetologia</i> , <b>1983</b> , 25, 120-2	10.3	1
3	A 6-hour nocturnal interruption of a continuous subcutaneous insulin infusion: 2. Marked attenuation of the metabolic deterioration by somatostatin. <i>Diabetologia</i> , <b>1983</b> , 24, 319-25	10.3	8

- 2 Influence of the A->G (-3826) uncoupling protein-1 gene (UCP1) variant on the dynamics of body weight before and after gastroplasty in morbidly obese subjects. *International Journal of Obesity* ,22, 1244-1245 5.5
- 1 Pharmacological Prevention of Type 2 Diabetes449-474 1